A
ADCT
Adc Therapeutics Sa
1.360
+0.040+3.03%After Hours: 1.360 0.000 0.00%19:30 09/04 EDT
OPEN/PREV CLOSE1.280/1.300
TODAY RANGE1.191-1.310
VOL1.71M
MARKET CAP155.75M
52 WEEK RANGE0.7796-4.980
AVG VOL (3M)1.49M
% TURNOVER1.34%
TURNOVER--
P/E (TTM)-1.6779
% RANGE9.15%
EPS(TTM)-0.7271
P/E(FORWARD)-1.6053
P/B-0.6813
BVPS-1.7907
DIVIDEND--
P/S1.886
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP133.30M
SHARES OUTSTANDING127.67M
NEXT EARNINGS11/09-11/13
FREE FLOAT109.26M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·08/25 00:11
ADC Therapeutics Balances Earnings Gains With Trial Risks
Dow Jones·08/17 13:45
ADC Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones·08/17 13:45
ADC Therapeutics Price Target Cut to $5.00/Share From $10.00 by Guggenheim
Benzinga·08/17 13:41
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5
TipRanks·08/17 11:07
ADC Therapeutics price target lowered to $5 from $10 at Guggenheim
TipRanks·08/17 08:04
ADC Therapeutics reports Q2 adjusted EPS (11c) vs. (25c) last year
Simply Wall St·08/14 22:44
ADC Therapeutics (ADCT) Stock Faces LOTIS 5 Doubts Despite Narrower Loss
TipRanks·08/14 14:25
RBC Capital Remains a Hold on ADC Therapeutics (ADCT)
TipRanks·08/13 13:49
ADC Therapeutics Reports Q2 2026 Results, Reassesses ZYNLONTA Path
Benzinga·08/13 13:05
ADC Therapeutics Q2 2026 Earnings Call Transcript
NASDAQ·08/13 12:50
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
Seeking Alpha·08/13 11:45
ADC Therapeutics Non-GAAP EPS of -$0.11, revenue of $19.25M beats by $0.35M
Seeking Alpha·08/12 19:06
ADC Therapeutics Q2 Earnings Preview
Same Industry
Name/Symbol
Change%
Price